No Pain, Lots To Gain: Vertex Looks For Non-Opioid Drug Breakthrough
Phase III Readout Expected By Early 2024
Vertex is closing in on annual revenues of $10bn from its cystic fibrosis drugs, but non-opioid pain therapy candidate VX-548 could open up a whole new blockbuster revenue stream if Phase III studies go to plan.
You may also be interested in...
A few years ago, investors were calling on Vertex to buy in late-stage innovation, but its focus on audacious drug development goals looks set to pay off with a groundbreaking CRISPR-based sickle cell disease cell therapy approaching the market. Its R&D head David Altshuler talked to Scrip about its approach.
Since 2017, BIO has noted a decline in pain therapy pipeline candidates, with a high attrition rate in the space and meager investment. The situation is grim for addiction-treatment therapy too, a new report points out.
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.